Antagonism between stem cells is not new. Competitive mechanisms are known to be critical for the modulation of organ homeostasis and regeneration. Competitive interaction within the niches results in survival of the fittest stem cells and death of the more vulnerable cells. An upregulation of c-myc transforms cells into supercompetitors capable of clonal expansion. The cluster of supercompetitors influences the behavior of the weakest surrounding cells, which are at a growth disadvantage. The presence of supercompetitors within niches regulates niche function, and the absence of supercompetitors may alter the preservation of stem cell self-renewal, leading to the generation of old dysfunctional niches. However, supercompetitor stem cells may fail to trigger apoptosis in the neighboring aging cells, promoting uncontrolled growth arrest and cellular senescence. This process may become excessive, favoring the formation of crowded niches where old stem cells predominate, opposing the activation of young functionally-competent stem cells. Thus, cooperative cell-to-cell communication may regulate more effectively the fate of stem cells within the niches, because the supporting cells transmit growth signals to stem cells according to the need of the organ and organism.

The concept of cooperation between stem cells and cardiomyocytes, functioning as supporting cells within the myocardial niches, has previously been documented, but the study by Williams et al in this issue of Circulation reports the cooperation between human mesenchymal stromal cells (MSCs) and human c-kit-positive cardiac stem cells (CSCs) after myocardial infarction in the swine heart. This clever approach has combined the regenerative potential of CSCs with the powerful secretory phenotype of MSCs. The low efficiency of transdifferentiation of MSCs has been overcome by the ability of the delivered CSCs to expand locally and create a large myocyte progeny, together with the required coronary microcirculation.

Despite the significant growth reserve of the human heart provided by the pool of resident CSCs, spontaneous cardiac repair does not occur after infarction, and the necrotic tissue is not restored by intact myocardium. Myocyte and vessel formation, mediated by activation and lineage specification of resident CSCs, is restricted to the surviving myocardium, whereas apoptosis of CSCs distributed within the ischemic region of the ventricular wall prevents tissue reconstitution, allowing the evolution of the healing process and the generation of a thick, nonfunctional scar. This inevitable progression of myocardial infarction establishes the basis for cell therapy and the search for the most appropriate cell for the replacement of a noncontracting scar with mechanically efficient cardiomyocytes, and arterioles and capillaries integrated with the main coronary circulation. The lack of endogenous regeneration after infarction is not restricted to the human heart but is present in solid and nonsolid organs, including the skin, liver, intestine, kidney, and bone marrow. In all cases, occlusion of a supplying artery leads to scar formation mimicking cardiac pathology. The stem cell compartment is properly equipped to regulate tissue homeostasis but does not respond effectively to ischemic injury, or late in life to aging and senescence of the organ and organism.

Shortly after the experimental evidence that hematopoietic stem cells induce myocardial regeneration after infarction, unfractionated mononuclear bone marrow cells and CD34-positive cells were administered to patients affected by acute and chronic myocardial infarction, dilated cardiomyopathy, and refractory angina. Although the individual outcomes have been inconsistent and variability exists among trials, meta-analyses of pooled data indicate that bone marrow cell therapy results in a 3% to 4% increase in ejection fraction, reduction in infarct size and left ventricular end-systolic volume, together with decreases in left ventricular end-diastolic volume, and improved survival. The positive consequences of bone marrow cells have consistently been documented regardless of the differences in the type of cells injected, choice of clinical end points, methods for the evaluation of cardiac function, and the interval between the onset of the cardiac disease and bone marrow cell infusion. A critical question, however, persists and will have to be answered; none of these trials has used c-kit-positive hematopoietic stem cells, which provided the initial experimental evidence of significant myocardial regeneration after infarction, resulting in a dramatic improvement of ventricular performance and a significantly decreased mortality in animal models of the human disease.

Recently, allogeneic and autologous bone marrow–derived MSCs have been used in small clinical trials, and encouraging results have been published. Although the benefits may seem modest, these initial data highlight the need for larger
randomized trials designed to critically evaluate the long-term effects of MSCs on a broader patient population. However, the mechanisms involved in the positive impact of MSCs on human beings remain to be identified. The impossibility to permanently label the cells to be delivered and the difficulty to obtain cardiac biopsies to assess parameters consistent with myocardial regeneration leaves uncertain our understanding of the cellular processes mediating partial myocardial recovery. Measurements of coronary blood flow suggest that vasculogenesis may be operative, although the contribution of de novo myocyte formation is uncertain. Reductions in infarct scar size speak in favor of myocardial regeneration, but unequivocal data have not been obtained yet. The most popular hypotheses include development of coronary vessels and enhanced blood supply to areas of hibernating myocardium, vasculogenesis and cardiomyogenesis, and growth activation and differentiation of resident CSCs via a paracrine effect, mediated by the release of a multiplicity of cytokines by the administered MSCs. The ability of MSCs to interfere with the relevant inflammatory response associated with ischemic myocardial injury adds value to the therapeutic efficacy of this class of primitive bone marrow cells.

Importantly, the identification of c-kit–positive CSCs (Figure 1) has shifted the attention to endogenous cell processes as novel targets of cell-based therapy for the failing heart. The appreciation that the heart is a dynamic organ constantly renewing its cell populations has generated great enthusiasm in the scientific and medical community. Understanding the mechanisms of cardiac homeostasis would offer the extraordinary opportunity to potentiate this naturally occurring process and promote myocardial regeneration after injury. Currently, a phase 1 clinical trial using autologous c-kit–positive CSCs is being completed with encouraging results.

An attempt to mimic in humans the strategy implemented by Williams et al in large animals has been made by delivering to patients with myocardial infarction cardiospheres derived from human MSCs. Cardiospheres contain a core of c-kit–positive primitive cells, several layers of differentiating cells expressing myocyte proteins and connexin 43, and an outer sheet composed of cells positive for CD105, a classic epitope of MSCs. Biologically, cardiospheres can be regarded as a simplified in vitro system of cardiac differentiation. But whether the utilization of cells already committed to the myocyte, endothelial cell, and smooth muscle cell lineages is preferable to the use of a pure population of undifferentiated human CSCs remains to be determined.

The protocol introduced experimentally in Dr Hare’s laboratory aims at the combination of an established clinically-relevant MSC with an equally documented effective undifferentiated, extensively characterized human c-kit–positive CSC. Conversely, the clinical use of cardiospheres, which are a partially defined heterogeneous cell preparation, may result in a greater array of unpredictable effects than a uniform population of identical cells with well-defined biological characteristics. In analogy with pharmacological approaches, the combination of different drugs in the same pill is coupled with ease of administration but may not allow dosage flexibility and personalized therapy. This is not the case in the approach used by Williams et al, in which the relative proportion of MSCs and CSCs was carefully controlled. In their study, 10 intramyocardial injections, each consisting of 20×10^6 MSCs and 10×10^4 CSCs, were used to rescue the infarcted myocardium in a large animal model.

Whether adjustments in the ratio between MSCs and CSCs are required, and whether repeated injections are needed to sustain over time the functional benefit, remains to be determined. If different classes of progenitor cells have to be tested, Dr Hare’s strategy offers a sophisticated carefully planned protocol that may not be initially perfect, but can be properly modified to reach the maximum effect in animals and, ultimately, in humans. The striking difference in the number of injected MSCs and CSCs makes a direct comparison between these 2 cell classes essentially impossible, but this has to be seen as the beginning of a more complex and demanding approach for the management of human ischemic cardiomyopathy. Clearly there is the need for more work to properly advance the field of cell therapy, which is currently in its infancy.

The remarkable recovery in the anatomic and functional integrity of the infarcted myocardium after combined cell therapy raises important questions concerning the mechanisms involved. The heart typically shows randomly oriented ellipsoid compartments where CSCs are clustered together forming myocardial niches. These pockets of CSCs are connected structurally and functionally to myocytes and fibroblasts that constitute the supporting cells within the niches; gap and adherens junctions made, respectively, by connexins and cadherins ensure the cooperative interaction regulating stem cell function and niche homeostasis.

Whether the administration of MSCs and CSCs leads to the formation of temporary or permanent niches within the host swine myocardium has not yet been resolved and constitutes

Figure 1. Clonal c-kit–positive human cardiac stem cells (CSCs). Single cell–derived clone in Terasaki plate. Human CSCs are self-renewing and clonogenic, fundamental properties of tissue-specific adult stem cells. c-kit, green; nuclei, DAPI, blue.
a major challenge for future research. The actual transfer of molecules between MSCs and CSCs remains to be shown to uncover the fundamental cellular processes involved in the extensive repair of the damaged heart.

Cardiac niches create the necessary, permissive milieu for the long-term residence and growth of CSCs. Similarly, the survival of exogenously administered stem cells requires their engraftment within the recipient myocardium. However, the region bordering the infarct is exposed to increased wall stress and functional demand, which promotes myocyte hypertrophy, activation of interstitial fibroblasts, and collagen accumulation. These variables may modify transiently the environment of the preexisting niches and prevent, at least in part, the formation of new temporary niches. The combination therapy applied by Dr Hare and his team may attenuate this possibly attenuating the stability and durability of cell-based therapy in its various forms. These issues are consistent with the questions posed by Dr Hare and his team, and collaborative efforts between laboratories with extensive experience in MSCs and CSCs are warranted in the search for the most powerful form of cell therapy for the injured human heart.

Sources of Funding

This work was supported by grants from the National Institutes of Health.

Disclosures

Dr Anversa is a member of Analogous, LLC. The other author reports no conflicts.

References

11. Hare JM, Traverse JH, Henry TD, Dib N, Strumpf RK, Schulman SP, Gerstenblith G, DeMaria AN, Denktas AE, Gammon RS, Hermiller JB...


**Key Words:** Editorials ■ cardiovascular diseases ■ stem cells
Stem Cells and Myocardial Regeneration: Cooperation Wins Over Competition
Annarosa Leri and Piero Anversa

Circulation. 2013;127:165-168; originally published online December 5, 2012;
doi: 10.1161/CIRCULATIONAHA.112.153973

Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2012 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the
World Wide Web at:
http://circ.ahajournals.org/content/127/2/165

An erratum has been published regarding this article. Please see the attached page for:
/content/132/22/e360.full.pdf

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published
in Circulation can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial
Office. Once the online version of the published article for which permission is being requested is located,
click Request Permissions in the middle column of the Web page under Services. Further information about
this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation is online at:
http://circ.ahajournals.org//subscriptions/
In the article by Leri and Anversa, “Stem Cells and Myocardial Regeneration: Cooperation Wins Over Competition,” which published online before print December 5, 2012, and appeared in the January 15, 2013, issue of the journal (Circulation. 2013;127:165-168. DOI: 10.1161/CIRCULATIONAHA.112.153973), a correction was needed.

Piero Anversa, MD, discloses that he is a member of Analogous, LLC.

The author regrets this omission.

This correction has been made to the current online version of the article, which is available at http://circ.ahajournals.org/content/127/2/165.full